TNF-alpha antagonist therapy modify the tuberculin skin test response
|
|
- Dylan Cameron
- 6 years ago
- Views:
Transcription
1 DOI /s ORIGINAL ARTICLE TNF-alpha antagonist therapy modify the tuberculin skin test response Tulin Cagatay Zeki Kilicaslan Penbe Cagatay Munevver Mertsoylu Ziya Gulbaran Reyhan Yildiz Leyla Pur Sevil Kamali Ahmet Gul Received: 18 November 2009 / Accepted: 10 March 2010 Ó Springer-Verlag 2010 Abstract Tumour necrosis factor-alpha (TNF-a) antagonist drugs have been associated with increased risk of tuberculosis (TB). Tuberculin skin test (TST) is the most frequently used tool for identification of latent TB infection. We herein aimed to analyse the effect of TNF-a antagonists on the TST responses in a prospective study. The study group consisted of 182 patients (99 female, 83 male) who received TNF-a antagonists for various rheumatic disorders. All T. Cagatay (&) Z. Kilicaslan M. Mertsoylu Z. Gulbaran R. Yildiz L. Pur Istanbul Faculty of Medicine, Department of Pulmonary Diseases, Istanbul University, Capa, Istanbul, Turkey tulcagat@istanbul.edu.tr Z. Kilicaslan zkaslan@istanbul.edu.tr M. Mertsoylu munevvermertsoylu@yahoo.com Z. Gulbaran ziyagulbaran@yahoo.com R. Yildiz drreyhanyildiz@yahoo.com L. Pur leylapur@yahoo.com P. Cagatay Cerrahpasa Faculty of Medicine, Department of Biostatistics, Istanbul University, Istanbul, Turkey penbecag@istanbul.edu.tr S. Kamali A. Gul Division of Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey kamalis@istanbul.edu.tr A. Gul agul@istanbul.edu.tr patients were evaluated with TST along with other parameters on the day of referral and on the 12th month visit. For those patients with a response of \5 mm induration at the initial evaluation, the TST was repeated to observe the booster effect. Out of 182 patients, 87 patients (48%) had a negative (0 4 mm) and 95 (52%) had a positive (C5 mm) TST response at initial evaluation. The TST responses were converted from negative at initial visit to positive at 1-year repeat in 26 (30%) patients. A significant increase was observed in the diameters of TST that were repeated on the first year of TNF-a antagonist treatment (9.15 ± 0.55) compared to their initial diameters (6.60 ± 0.51) (P \ 0.001). Increased TST responses in patients receiving TNF-a antagonists may be associated with the restoration of suppressed immune reactivity against TB antigens with the decreased disease activity. The meaning of TST conversion in the definition of latent TB infection and the need for chemoprophylaxis in these patients remains to be answered by further studies. Keywords Tuberculin skin test (TST) Tumour necrosis factor (TNF)-a antagonist drugs Latent tuberculosis infection Rheumatoid arthritis Ankylosing spondylitis Introduction Tuberculosis (TB) is among the most frequent causes of death from infection in humans, accounting for around 1.6 million deaths annually [1]. Reactivation of a latent Mycobacterium tuberculosis infection can cause an important morbidity and mortality, especially among immunocompromised individuals [2]. Tumour necrosis factor-alpha (TNF-a) antagonist drugs (infliximab,
2 etanercept and adalimumab) are being frequently used in the treatment of various inflammatory rheumatic or other multisystem disorders, such as rheumatoid arthritis, ankylosing spondylitis and inflammatory bowel diseases; and an increased risk of TB and other infectious diseases has been documented in patients receiving TNF-a antagonist treatments. Therefore, all patients who will be treated with these agents have been screened for TB infection, and identification of the latent TB infection has again become an important topic of investigation [3, 4]. Tuberculin skin test (TST) is still the most frequently used and inexpensive test for identification of latent TB infection. TST is a classical delayed-type hypersensitivity (DTH) response to the intradermal injection of tuberculin antigen, and it represents a cutaneous T cell-mediated immune response. However, the accuracy and reliability of TST are significantly affected by immunosuppressive therapy and/or the activity of the underlying inflammatory disorders [5, 6]. At present, there is no standard method to diagnose latent TB infection reliably in patients receiving immunosuppressant drugs or having an immunocompromised condition. Most of the guidelines accept a 5-mm TST response as an indication of latent infection after the exclusion of active disease and recommend the treatment of latent TB infection with isoniazid or alternatives [7, 8]. Blockade of TNF-a action by these drugs can affect cellular immune responses and granuloma formation [9]. Though there are accumulating data about the association of these agents with an increased risk for TB infection, little is known about their effect on TST response [10]. Therefore, we herein aimed to analyse the effect of TNF-a antagonists on the TST responses in a prospective study. Materials and methods Patients The study group comprised those 182 patients (99 women, 83 men) who were followed-up at least for a year among a pool of 481 patients who were referred to the Department of Pulmonary Diseases for the evaluation of TB infection before starting a TNF-a antagonist agent. The underlying pathologies were rheumatoid arthritis in 82 patients (45.1%), ankylosing spondylitis in 51 (28%), psoriatic arthritis and other disorders in the remaining 49 (26.9%) patients. The Ethics Committee of Istanbul Faculty of Medicine approved the study protocol, and a written informed consent was obtained from all patients. All patients were evaluated with history, physical examination, chest radiograph and TST on the day of referral. Further investigations such as thorax CT, direct smear and cultures for mycobacteriae when a suspicious lesion was detected. The TST was done to the left forearm of the patients using at five Tuberculosis Control Units of tuberculin, and the response was evaluated as the diameter of induration at 72 h of injection. For those patients with a response of \5-mm induration, the TST was repeated 7 10 days later to observe the booster effect. Patients with a TST response of C5-mm induration and having no findings of active TB disease or a history of close contact with a patient with TB were given 5 mg/kg of isoniazid (maximum 300 mg/day) chemoprophylaxis for 9 months according to the local guideline for the treatment of latent infection. Patients receiving TNF-a antagonists were monitored with 2-monthly visits, and a repeat TST and chest radiograph were obtained from all patients as well as a detailed history of a new TB contact and clinical symptoms during the 12th month visit. Statistical analysis Statistical analyses were conducted using Unistat 5.1 software. All numerical values are reported as mean ± SE. The TST response variability as changes in induration diameters were compared with a non-parametric Wilcoxon test. The parameters which may potentially affect the TST responses were tested using a logistic regression analysis. P values \0.05 were considered as significant. Results Demographic and clinical characteristics of the patients are shown in Table 1, and the mean diameters of the first and second TST responses in all patients are shown in Table 2. None of the patients developed active TB disease during the follow-up. Out of 182 patients, 87 patients (47.8%) had a negative (0 4 mm) and 95 (52.2%) had a positive (C5 mm) TST response at the initial evaluation. A total of 156 patients including all patients with a negative TST response and patients with an abnormal chest radiograph consistent with past TB or a history of close contact were given isoniazid chemoprophylaxis for 9 months. After 1 year exposure to TNF-a antagonist agents, 61 out of 182 patients (33.5%) had a negative and 121 (66.5%) had positive TST responses (Table 2). In a subgroup analysis of patients with rheumatoid arthritis, 48 out of 82 patients (58.5%) had a negative TST response at the initial visit, and the TST responses were converted to positive in 12 of them (25%) after 1-year treatment with TNF-a antagonist drugs (Table 3). In 51 patients with ankylosing spondylitis, 17 (33.3%) patients had a negative TST response, and the TST responses were converted to positive
3 Table 1 Characteristics of the patients receiving TNF-a antagonist drugs for 1 year n % Mean ± SE Age ± 1.09 Sex Female Male Smoking habit Yes No Cigarette Packages/year ± 1.53 Rheumatic disease Rheumatoid arthritis Ankylosing spondylitis Psoriatic arthritis and others Disease duration (years) (n = 182) ± 0.51 Other drug use duration (months) ± 0.89 (n = 182) Tuberculosis contact Yes No History of TB Regular treatment Yes No BCG Yes No Use of isoniazid Yes No Hepatotoxicity Yes No Chest X-ray Lesion (I) Yes No in 7 (41.1%) of them (Table 3). In total, the TST responses were converted from negative at initial visit to positive at 1-year repeat in 26 (29.8%) patients, and the TST responses stayed negative in 61 patients (70.2%) after 1-year exposure to TNF-a antagonists. The mean TST response of patients with rheumatoid arthritis was found to be smaller than those of patients with ankylosing spondylitis, but the difference between those patients was not statistically different (Table 3). We observed a significant increase in the induration diameters of TST responses that were repeated on the first Table 2 Tuberculin skin test (TST) results of the patients who received TNF-a antagonists for 1 year year of TNF-a antagonist treatment (9.15 ± 0.55) compared to their initial diameters (6.60 ± 0.51) (P \ 0.001, Table 2). We found that the majority of patients with a 0-mm induration at their first TST (n = 81) had also a negative result in their second TSTs (n = 54). When those patients with a negative TST in the last screen were excluded from the analysis, the remaining patients second TST response diameters were again found to be significantly increased compared to their first diameters (Table 2). The increase of TST diameter at first year visit compared to their initial values was significant in all subgroups of patients (Table 3). Logistic regression analysis revealed no effect of age, sex, smoking, underlying inflammatory condition, type and duration of immunosuppressive treatments, past TB history, positive family history or a close contact, BCG vaccination or isoniazid chemoprophylaxis when we grouped the patients as those with an increased TST response and others. Discussion n Mean ± SE P TST TST ± 0.51 \0.001 TST-1 year ± 0.55 Excluding TST 0 mm (1 year) TST ± 0.58 \0.001 TST-1 year ± 0.47 TST-0: Induration diameter of the tuberculin prior to TNF antagonist treatment TST-1 year: Induration diameter of the tuberculin after 1 year use of TNF antagonist treatment In this study, we prospectively investigated the effect of TNF-a antagonist drugs on the diameter of TST induration in a group of patients with inflammatory rheumatic conditions, and we observed a significant increase in the diameter of TST following a 1-year exposure to TNF-a antagonist drugs. Reactivation of latent M. tuberculosis infection is a major complication of TNF-a antagonist treatment, but its mechanism is not fully understood. Identification of those patients with a latent TB infection is very important before starting a TNF-a antagonist treatment. TST is still the most commonly used and inexpensive tool for the investigation of latent TB infection, although interferon-gamma (IFN-c) release assays (IGRAs) have started to be used in recent years for providing more information in the diagnosis of
4 Table 3 Comparison of the tuberculin skin test (TST) results in subgroups of patients with different rheumatic disorders Rheumatic disorder TST-0 (%) TST-1 year (%) Rheumatoid arthritis (n = 82) TST \ 5 mm 48 (58.5%) 36 (43.9%) TST C 5 mm 34 (41.5%) 46 (56.1%) Induration diameter (mm) (mean ± SE) 5.20 ± ± 0.82 (P \ 0.01) Ankylosing spondylitis (n = 51) TST \ 5 mm 17 (33.3%) 10 (19.6%) TST C 5 mm 34 (66.7%) 41 (80.4%) Induration diameter (mm) (mean ± SE) 8.59 ± ± 0.97 (P \ 0.001) Psoriatic arthritis and others (n = 49) TST \ 5 mm 22 (45%) 15 (30.6%) TST C 5 mm 27 (55%) 34 (69.4%) Induration diameter (mm) (mean ± SE) 6.88 ± ± 1.04 (P \ 0.001) latent infection especially in those patients with an immunocompromised condition [4, 11 13]. According to the recent recommendations, a chemoprophylaxis with isoniazid for up to 9 months is advised for patients with a tuberculin test diameter of C5 mm and who will receive TNF-a antagonist drugs. TNF-a antagonist drugs are mostly used in patients with an autoimmune or autoinflammatory disorder who have not responded to standard antiinflammatory or immunosuppressant drugs. The delayed type hypersensitivity is considered to be suppressed in immunocompromised patients. Therefore, it may not be possible to obtain a reliable response to the skin tests [2]. An anergic reaction to delayed type hypersensitivity tests such as TST in patients with chronic arthritis may result from disease activity, immunosuppressive treatment, or both. Some investigators showed that there could be an improvement in delayed type hypersensitivity response in patients receiving disease modifying anti-rheumatic drugs, but the actual effect of TNF-a antagonists on TST has not yet been studied in detail [14]. In a recent study, Joven et al. [10] reported an increase in diameter of TST in a smaller group of patients receiving TNF-a antagonists. Our findings support Joven et al. s observations in a larger series of patients, which also allowed to do a subgroup analysis in patients with rheumatoid arthritis and ankylosing spondylitis. We found that a significant increase in the diameter of TST can be expected in patients who received anti-tnf-a agents for 1 year as well as a conversion from negative TST to positive in a considerable amount of patients (30%). None of the patients described a contact with a patient with TB and none developed a clinical, radiological or bacteriological sign in favour of an active TB infection during 1-year follow-up. At the same time, none of the patients received INH treatment for tuberculosis prophylaxy. These observations suggest that increase in the diameter of TST response may be associated with TNF-a antagonist treatment, and evaluation of latent TB infection should be repeated at certain intervals. The main proinflammatory cytokines in TB pathogenesis are TNF-a that are produced by activated macrophages and T cells, and IFN-c produced by CD4, CD8 and cd T cells as well as natural killer cells [15, 16]. Both of these cytokines participate in granuloma formation, and TNF-a synergizes with IFN-c in its tuberculostatic activity [17 19]. This can explain the higher incidence of TB seen in patients receiving anti-tnfa treatment. However, steady TNF-a production during chronic TB is not without cost to the host, resulting in cachexia and weight loss in advanced disease [20]. It is known that serum TNF-a levels are increased in patients with rheumatoid arthritis [21, 22], but there are different findings on the effects of TNF-a antagonists on serum TNF-a levels. There is no detailed information about the effect of TNF-a antagonists on the TST response in rheumatoid arthritis patients. It was reported that delayed type hypersensitivity response was decreased in rheumatoid arthritis patients examined by the multitest technique, and TST response was improved following treatment with gold salts [14]. Therefore, it can be suggested that elevated expression of proinflammatory cytokines including TNF-a can suppress the TST response, and the expected TST response can be restored after the anti TNF-a treatment. On the other hand, improvement of TST response may also be associated with the tapering of other immunosuppressive drugs including corticosteroids during the TNF-a antagonist treatment. In this study, we observed that TNF-a antagonist treatment does not decrease the delayed type hypersensitivity reaction, but on the contrary, an increased TST response can be seen in patients receiving these agents, which may suggest the restoration of suppressed immune reactivity against TB antigens with the decreased disease activity. No data could be reached for the effect of INH prophylaxis on TST diameter but theoretically it can be said
5 that INH has no effect on TST or even has a decreasing effect. Furthermore the effect of INH is out of question in this group of patients with negative TST and who are converted to a positive TST after a 1 year s TNF treatment as they did not receive INH at all during this period. Our second hypotheses may not have an impact upon the explanation of the conversion to a positive TST due to the diminution of the disease activation, leading to the vanishing of the immune suppression because in all the patient groups who are either immune suppressive or non-immune suppressive (RA, ankylosing spondylitis, psoriasis and others), all showed a conversion from negative to positive. Therefore, this conversion and TST diameter increase may be attributed to TNF-a antagonist treatment. We conclude that during the TNF-a antagonist treatment, a repeated TST may be beneficial since a conversion from negative to positive in as much as 30% of the patients at the 1-year follow-up of anti-tnf-a therapy can be observed. The meaning of this TST conversion in the definition of latent TB infection and the need for chemoprophylaxis in these patients remains to be answered by further studies. Conflict of interest statement References None. 1. World Health Organization (2007) WHO report 2007: global tuberculosis control: surveillance, planning, financing. WHO, Geneva 2. Sester U, Junker H, Junker H et al (2006) Improved efficiency in detecting cellular immunity towards M. tuberculosis in patients receiving immunosuppressive drug therapy. Nephrol Dial Transplant 21: Saliu OY, Sofer C, Stein DS et al (2006) Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. J Infect Dis 194: Dukes HC (2004) Infectious complications of treatment with biologic agents: infectious arthritis and immune dysfunction. Curr Opin Rheumatol 16: Vukmanovic-Stejic M, Reed JR, Lacy KE et al (2006) Mantoux test as a model for a secondary immune response in humans. Immunol Lett 107: Helliwell MG, Panayi GS, Unger A (1984) Delayed cutaneous hypersensitivity in rheumatoid arthritis: the influence of nutrition and drug therapy. Clin Rheumatol 3: Furst DE, Breedveld FC, Kalden JR et al (2003) Updated consensus statement on biological agents for treatment of rheumatoid arthritis and other immune mediated inflammatory diseases. Ann Rheum Dis 62(Suppl 2): Thoracic Society Standards of Care Committee (2005) BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-tnf-a treatment. Thorax 60: Hamdi H, Mariette X, Godot V et al (2006) The RATIO (Recherche sur Anti-TNF et Infections Opportunistes) Study Group. Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. Arthritis Res Ther 8:R Joven BE, Almodóvar R, Galindo M et al (2006) Does antitumour necrosis factor a treatment modify the tuberculin TST response? Ann Rheum Dis 65: Hill PC, Jeffries DJ, Brookes RH et al (2007) Using ELISPOT to expose false positive skin test conversion in tuberculosis contacts. PLoSONE 2: Kunst H (2006) Diagnosis of latent tuberculosis infection: the potential role of new technologies. Respir Med 100: Codecasa LR, Ferrarese M, Penati V et al (2005) Comparison of tuberculin skin test and Quantiferon immunological assay for latent tuberculosis infection. Monaldi Arch Chest Dis 63: Smith MD, Smith A, O Donnell J et al (1989) Impaired delayed type cutaneous hypersensitivity in rheumatoid arthritis reversed by chrysotherapy. Ann Rheum Dis 48: Kerksiek KM, Pamer EG (1999) T cell responses to bacterial infections. Curr Opin Immunol 11: Ogawa T, Uchida H, Kusumoto Y et al (1991) Increase in tumor necrosis factor a and interleukin-6 secreting cells in peripheral blood mononuclear cells from subjects infected with Mycobacterium tuberculosis. Infect Immun 59: Bermudez LE, Kaplan G (1995) Recombinant cytokines for controlling mycobacterial infections. Trends Microbiol 3: Kindler V, Sappino AP, Grau GE et al (1989) The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 56: Flesch IEA, Kaufmann SHE (1990) Activation of tuberculostatic macrophage functions by interferon gamma, interleukin 4 and tumor necrosis factor. Infect Immun 58: Hussain R, Shiratsuchi H, Phillips M et al (2001) Opsonizing antibodies (IgG1) up-regulate monocyte proinflammatory cytokines tumour necrosis factor-a (TNF-a) and IL-6 but not antiinflammatory cytokine IL-10 in mycobacterial antigen-stimulated monocytes implications for pathogenesis. Clin Exp Immunol : Pachot H, Arnaud B, Marrote H et al (2007) Increased tumor necrosis factor-a mrna expression in whole blood from patients with rheumatoid arthritis: reduction after infliximab treatment does not predict response. J Rheumatol 34: Marotte H, Maslinski W, Miossec P (2005) Circulating tumour necrosis factor-a bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response. Arthritis Res Ther 7:
LATENT TUBERCULOSIS. Robert F. Tyree, MD
LATENT TUBERCULOSIS Robert F. Tyree, MD 1 YK TB OFFICERS Ron Bowerman Elizabeth Roll Mien Chyi (Pediatrics) Cindi Mondesir (Pediatrics) The new guys: Philip Johnson Robert Tyree 2009 CDC TB CASE DEFINITION
More informationDimitrios Vassilopoulos,* Stamatoula Tsikrika, Chrisoula Hatzara, Varvara Podia, Anna Kandili, Nikolaos Stamoulis, and Emilia Hadziyannis
CLINICAL AND VACCINE IMMUNOLOGY, Dec. 2011, p. 2102 2108 Vol. 18, No. 12 1556-6811/11/$12.00 doi:10.1128/cvi.05299-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Comparison
More informationTuberculosis and Biologic Therapies: Risk and Prevention
Tuberculosis and Biologic Therapies: Risk and Prevention Kevin L. Winthrop, MD, MPH Associate Professor, Divisions of Infectious Diseases, Public Health and Preventive Medicine Oregon Health & Science
More informationTuberculosis Tools: A Clinical Update
Tuberculosis Tools: A Clinical Update CAPA Conference 2014 JoAnn Deasy, PA-C. MPH, DFAAPA jadeasy@sbcglobal.net Adjunct Faculty Touro PA Program Learning Objectives Outline the pathogenesis of active pulmonary
More informationTable 9. Policy for Tuberculosis Surveillance and Screening
Policy for Tuberculosis Surveillance and Screening Purpose: to identify active cases of tuberculosis or latent TB among residents and staff of the nursing home in order to prevent transmission in this
More informationESCMID Online Lecture Library. by author
Tuberculosis prevention in immunodepressed patients M. Carmen Fariñas Álvarez Infectious Diseases.H.U.Marqués de Valdecilla University of Cantabria, Spain DISCLOSURES I have no potential conflicts with
More informationDiagnosis Latent Tuberculosis. Disclosures. Case
Diagnosis Latent Tuberculosis Neha Shah MD MPH Field Medical Officer Tuberculosis Control Branch California Department of Public Health Centers for Disease Control and Prevention September 2016 1 Disclosures
More informationJennifer Lam MPH candidate 2009 Johns Hopkins Bloomberg School of Public Health. Preceptors: Wendy Cronin, PhD MT(ASCP), Cathy Goldsborough, RN
Jennifer Lam MPH candidate 2009 Johns Hopkins Bloomberg School of Public Health Preceptors: Wendy Cronin, PhD MT(ASCP), Cathy Goldsborough, RN Phase Symposium: May 6, 2009 Background & Rationale Maryland
More informationTB testing in children on biologics
TB testing in children on biologics Version: 1 Approval Committee: Date of Approval: Ratification Group (eg Clinical network): Date of Ratification Signature of ratifying Group Chair Author(s) and title
More informationCHAPTER 3: DEFINITION OF TERMS
CHAPTER 3: DEFINITION OF TERMS NOTE: TB bacteria is used in place of Mycobacterium tuberculosis and Mycobacterium tuberculosis complex in most of the definitions presented here. 3.1 Acid-fast bacteria
More informationLet s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year
A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Madhukar Pai, MD, PhD Author and Series Editor Camilla Rodrigues, MD co-author Abstract Most individuals who get exposed
More informationIn our paper, we suggest that tuberculosis and sarcoidosis are two ends of the same spectrum. Given the pathophysiological and clinical link between
In our paper, we suggest that tuberculosis and sarcoidosis are two ends of the same spectrum. Given the pathophysiological and clinical link between the two, we also propose a classification system for
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
TB Partial Update Appendix 1 - Scope NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Tuberculosis: interferon gamma tests for the diagnosis of latent tuberculosis (partial
More informationNorthwestern Polytechnic University
Clinical Tuberculosis Assessment by Health Care Provider Clinicians should review and verify the information in the Tuberculosis (TB) Screening Questionnaire (attached). Persons answering YES to any questions
More informationCommunicable Disease Control Manual Chapter 4: Tuberculosis
Provincial TB Services 655 West 12th Avenue Vancouver, BC V5Z 4R4 www.bccdc.ca Communicable Disease Control Manual Definitions Page 1 2.0 DEFINITIONS Many of the definitions that follow are taken from
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Tuberculosis: interferon gamma tests for the diagnosis of latent tuberculosis (partial update) 1.1 Short title Tuberculosis
More informationRepeated tuberculin skin testing following therapy with TNF-alpha inhibitors
Clin Rheumatol (2009) 28:167 172 DOI 10.1007/s10067-008-1007-9 ORIGINAL ARTICLE Repeated tuberculin skin testing following therapy with TNF-alpha inhibitors Inbal Fuchs & Lone Avnon & Tamar Freud & Mahmoud
More informationIdentification of latent tuberculosis infection in rheumatic patients under consideration for treatment with anti-tnf-α agents
Clinical research Identification of latent tuberculosis infection in rheumatic patients under consideration for treatment with anti-tnf-α agents Jolanta Paluch-Oleś 1, Agnieszka Magryś 1, Maria Kozioł-Montewka
More informationDENOMINATOR: All patients aged 18 and older with a diagnosis of inflammatory bowel disease
Measure #274: Inflammatory Bowel Disease (IBD): Testing for Latent Tuberculosis (TB) Before Initiating Anti-TNF (Tumor Necrosis Factor) Therapy National Quality Strategy Domain: Effective Clinical Care
More informationPREVENTION OF TUBERCULOSIS. Dr Amitesh Aggarwal
PREVENTION OF TUBERCULOSIS Dr Amitesh Aggarwal 25 to 50 % of persons exposed to intimate contact with active PTB - latent infection with TB. Exposure to index case for 12 hours - high risk of infection.
More information10/3/2017. Updates in Tuberculosis. Global Tuberculosis, WHO 2015 report. Objectives. Disclosures. I have nothing to disclose
Disclosures Updates in Tuberculosis I have nothing to disclose Chris Keh, MD Assistant Clinical Professor, Division of Infectious Diseases, UCSF TB Controller, TB Prevention and Control Program, Population
More informationDetecting latent tuberculosis infection during anti-tumour necrosis factor therapy
Detecting latent tuberculosis infection during anti-tumour necrosis factor therapy J.S. Ringrose 1, S.E. Sanche 2, R.M. Taylor-Gjevre 3 1 Division of General Internal Medicine, Department of Medicine,
More informationCase reports. Patient 1
REVIEW ARTICLE BJD British Journal of Dermatology Tuberculosis and tumour necrosis factor-a inhibitor therapy: a report of three cases in patients with psoriasis. Comprehensive screening and therapeutic
More informationA Clinician s Perspective: Improving Rheumatology Patient Care Using the T-SPOT.TB Test
A Clinician s Perspective: Improving Rheumatology Patient Care Using the T-SPOT.TB Test Solomon Forouzesh, MD, FACD, FACR Medical Director Arthritis Care & Treatment Center Clinical Associate Professor
More informationLatent Tuberculosis Infection Reporting Instructions for Civil Surgeons Using CalREDIE Provider Portal
Latent Tuberculosis Infection Reporting Instructions for Civil Surgeons Using CalREDIE Provider Portal Civil surgeons are required to report tuberculosis (TB) screening outcomes that result in latent TB
More informationA look at medical factors that increase the risk for TB disease
A look at medical factors that increase the risk for TB disease Mark Lobato, MD New England TB Consultant Division of Tuberculosis Elimination CDC Overview The spectrum of M. tuberculosis infection Immune
More informationIdentifying TB co-infection : new approaches?
Identifying TB co-infection : new approaches? Charoen Chuchottaworn MD. Senior Medical Advisor, Central Chest Institute of Thailand, Department of Medical Services, MoPH Primary tuberculosis Natural history
More informationTUBERCULOSIS AND THE TNF-α INHIBITORS. Lloyd Friedman, M.D. Yale University Milford Hospital
TUBERCULOSIS AND THE TNF-α INHIBITORS Lloyd Friedman, M.D. Yale University Milford Hospital Outline TNF-α Anti-TNF-α medications Rates of tuberculosis Lower rates with etanercept Screening for latent tuberculosis
More informationESCMID Online Lecture Library. by author
Therapies or diseases predisposing to infection Congenital immunodeficiences Acquired conditions Common variable immunedeficiency particular diseases (e.g. HIV, cancer,leukemia, lymphoma, diabetes, cystic
More informationTuberculosis and Diabetes Mellitus. Lana Kay Tyer, RN MSN WA State Department of Health TB Nurse Consultant
Tuberculosis and Diabetes Mellitus Lana Kay Tyer, RN MSN WA State Department of Health TB Nurse Consultant Learning Objectives Understand the impact of uncontrolled diabetes mellitus (DM) on TB infection
More informationPeggy Leslie-Smith, RN
Peggy Leslie-Smith, RN EMPLOYEE HEALTH DIRECTOR - AVERA TRAINING CONTENT 1. South Dakota Regulations 2. Iowa Regulations 3. Minnesota Regulations 4. Interferon Gamma Release Assay (IGRA)Testing 1 SOUTH
More informationThe GPs role with biologics for immune-mediated inflammatory diseases David Gardner Rheumatologist GPCME 2015
The GPs role with biologics for immune-mediated inflammatory diseases David Gardner Rheumatologist GPCME 2015 The views and opinions expressed in the following presentation are those of the presenter and
More informationLatent tuberculosis (TB) infection (LTBI), a
COMMENTARY Time for a change? Updated guidelines using interferon gamma release assays for detection of latent tuberculosis infection in the office setting Marisa Kardos, BS, and Alexa Boer Kimball, MD,
More informationApproaches to LTBI Diagnosis
Approaches to LTBI Diagnosis Focus on LTBI October 8 th, 2018 Michelle Haas, M.D. Associate Director Denver Metro Tuberculosis Program Denver Public Health DISCLOSURES I have no disclosures or conflicts
More informationInterferon Gamma Release Assay Testing for Latent Tuberculosis Infection: Physician Guidelines
Interferon Gamma Release Assay Testing for Latent Tuberculosis Infection: Physician Guidelines Historically, Latent Tuberculosis Infection (LTBI) diagnosis was based on risk assessment, chest x-ray (CXR)
More informationAnti-TNF medication and tuberculosis
Anti-TNF medication and tuberculosis Marleen Bakker Amsterdam 23-09-14 Contents Why? Who? How? How? - 1 - testing + interpretation - 2 treatment Why? Blocking TNF has major effect on immune-mediated inflammatory
More informationTuberculosis screening in pediatric patients receiving TNFalpha inhibitor therapy
The Turkish Journal of Pediatrics 2017; 59: 503-510 DOI: 10.24953/turkjped.2017.05.001 Original Tuberculosis screening in pediatric patients receiving TNFalpha inhibitor therapy Manolya Acar 1, Murat Sütçü
More informationTB Prevention Who and How to Screen
TB Prevention Who and How to Screen 4.8.07. IUATLD 1st Asia Pacific Region Conference 2007 Dr Cynthia Chee Dept of Respiratory Medicine / TB Control Unit Tan Tock Seng Hospital, Singapore Cycle of Infection
More informationDiagnosis & Management of Latent TB Infection
Diagnosis & Management of Latent TB Infection Prof. Ashok Rattan, MD, MAMS, INSA DFG, WHO Lab Director Academics, Industry: Research, Diagnosis, Public Health, Academics Adviser: Laboratory Operations,
More informationLatent TB Infection (LTBI)
Latent TB Infection (LTBI) Diagnosis & Treatment of Latent TB Infection (LTBI) Amee Patrawalla MD MPH Assistant Professor UMDNJ-New Jersey Medical School Infection with Mycobacterium tuberculosis without
More informationTB Intensive San Antonio, Texas December 1-3, 2010
TB Intensive San Antonio, Texas December 1-3, 2010 TB Pathogenesis and Transmission Lynn Horvath, MD; TCID December 1, 2010 Tuberculosis Pathogenesis Lynn L. Horvath, MD, FACP, FIDSA Associate Professor
More informationWhy need to havetb Clearance. To Control and Prevent Tuberculosis
Why need to havetb Clearance To Control and Prevent Tuberculosis How to ID Tuberculosis There are two kinds of tests that are used to determine if a person has been infected with TB bacteria: the tuberculin
More informationTuberculosis Education for the Medical Professional
Tuberculosis Education for the Medical Professional North Dakota Diagnosis and Medical Management of Latent TB Infection Dawn Farrell, RN, BSN, PHN Maria Robles, BSN July 10, 2007 Tuberculosis Education
More informationTuberculosis and TNF Inhibitors
Tuberculosis and TNF Inhibitors Sundari Mase MD, MPH Medical Team Lead CDC/DTBE/FSEB January 18, 2011 Objectives Discuss the association between and epidemiology of TNF inhibitors and TB Discuss the challenges
More informationTargeted Testing and the Diagnosis of. Latent Tuberculosis. Infection and Tuberculosis Disease
Self-Study Study Modules on Tuberculosis Targeted Testing and the Diagnosis of Latent Tuberculosis Infection and Tuberculosis Disease 1 Module 3: Objectives At completion of this module, learners will
More informationNguyen Van Hung (NTP, Viet Nam)
Technical Consultation Meeting on the Programmatic Management of Latent Tuberculosis Infection 31 August-1 September 2017, Seoul, Republic Korea Adopting new LTBI diagnostics at country level: perspective
More informationTuberculosis Intensive
Tuberculosis Intensive San Antonio, Texas April 3 6, 2012 Tuberculosis Pathogenesis Lynn Horvath, MD April 3, 2012 Lynn Horvath, MD has the following disclosures to make: No conflict of interests No relevant
More informationTuberculosis Pathogenesis
Tuberculosis Pathogenesis Renuka Khurana, MD, MPH May 12, 2015 TB for Community Providers May 12, 2015 Phoenix, Arizona EXCELLENCE EXPERTISE INNOVATION Renuka Khurana, MD, MPH has the following disclosures
More informationUnderstanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010
Understanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010 What is Latent TB Infection (LTBI)? Traci Hadley, RN October 5, 2010 LTBI or TB Disease? Presented by : Traci Hadley, RN
More informationSelf-Study Modules on Tuberculosis
Self-Study Modules on Tuberculosis Targe te d Te s ting and the Diagnosis of Latent Tuberculosis Infection and Tuberculosis Disease U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control
More informationLatent Tuberculosis Infection (LTBI) Questions and Answers for Health Care Providers
Latent Tuberculosis Infection (LTBI) Questions and Answers for Health Care Providers Who Should Be Screened for Latent Tuberculosis Infection (LTBI)?... 2 What tests are used to screen for LTBI?... 2 How
More informationTUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of
TUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of Health and Mental Hygiene TODAY S PRESENTATION Epidemiology
More informationPathogenesis of Rheumatoid Arthritis. Smolen, J. S. et al. (2012) Nat. Rev. Rheumatol. doi: /nrrheum
1 Pathogenesis of Rheumatoid Arthritis 2 Smolen, J. S. et al. (2012) Nat. Rev. Rheumatol. doi:10.1038/nrrheum 2012.23 Biologic therapies used in the treatment of rheumatoid arthritis 3 Etanercept Infliximab
More informationLATENT TUBERCULOSIS SCREENING AND TREATMENT:
LATENT TUBERCULOSIS SCREENING AND TREATMENT: TB or not TB Christopher Kwong, MD and William Rifkin, MD Week 14 Educational Objectives: 1. Understand who should be screened for latent TB infection and why
More informationTuberculosis Update. Topics to be Addressed
Tuberculosis Update Robert M. Jasmer, M.D. University of California, San Francisco TB Control Section, San Francisco Department of Public Health Topics to be Addressed TB in the USA Screening recommendations
More informationActemra (tocilizumab) CG-DRUG-81
Market DC Actemra (tocilizumab) CG-DRUG-81 Override(s) Prior Authorization Approval Duration 1 year Medications Line of Business Quantity Limit Actemra (tocilizumab) vials VA MCD and All L-AGP May be subject
More informationCategory Description / Key Findings Publication
PUBLICATIONS Selected T-SPOT.TB test publications, by area of interest, up to 31 th August 2016. Category Description / Key Findings Publication Background A useful primer on the evolution, administration
More informationTechnical Bulletin No. 172
CPAL Central Pennsylvania Alliance Laboratory QuantiFERON -TB Gold Plus Assay Contact: J Matthew Groeller, MPA(HCM), MT(ASCP), 717-851-4516 Operations Manager, Clinical Pathology, CPAL Jennifer Thebo,
More informationTargeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University
Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University Tuberculosis Estimates USA World Infection 15,000,000 2,000,000,000
More informationSanta Clara County Tuberculosis Screening Requirement for School Entrance Effective June 1, 2014
Guidelines to Revisions to the School Mandate and Requirements 1) What are the tuberculosis (TB) screening requirements for school entrance in Santa Clara County? Students must undergo a TB risk assessment
More informationT-CELL RESPONSES ASSESSED USING IGRA AND TST ARE NOT CORRELATED WITH AFB GRADE AND CHEST RADIOGRAPH IN PULMONARY TUBERCULOSIS PATIENTS
T-CELL RESPONSES ASSESSED USING IGRA AND TST ARE NOT CORRELATED WITH AFB GRADE AND CHEST RADIOGRAPH IN PULMONARY TUBERCULOSIS PATIENTS Kiatichai Faksri 1, 4, Wipa Reechaipichitkul 2, 4, Wilailuk Pimrin
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: golimumab_simponi 8/2013 2/2018 2/2019 3/2018 Description of Procedure or Service Golimumab (Simponi and
More informationLatent Tuberculosis in Adults: From Testing TO Treatment
Latent Tuberculosis in Adults: From Testing TO Treatment Sergio M. Borgia, MD, MSc., FRCP(C) Infectious Diseases Consultant, WOHS Medical Director, WOHS Tuberculosis Clinic Assistant Clinical Professor,
More informationBCG in Tower Hamlets. Luise Dawson Public Health Nurse
BCG in Tower Hamlets Luise Dawson Public Health Nurse Coverage levels of BCG for infants under 1 year 100% 90.9% 95.5% 95.0% 98.7% 90% 81% 82% 80% 70% 60% 50% 40% 30% 20% 10% 0% March 0708 March 0809 March
More information(2) 83.3% b/w TST and T-SPOT, (2) 77.4% b/w TST and T-SPOT. 77.7% b/w TST and QFT-GIT. QFT-GIT, 22.2% in T-SPOT. TSPOT vs. TST (> 5 mm) vs.
Supplementary Table 1. Study characteristics of the included literature Low to moderate TB endemic region Shovman et al. (2009) [21] Minguez et al. (2012) [16], type 35 RA 35 RA 53 Patients with s (RA
More informationLTBI Treatment and Anti TNF alpha
LTBI Treatment and Anti TNF alpha Therapy Julie Higashi, MD PhD Director, TB Control Section San Francisco Department of Public Health TNF alpha is important for the immune response against TB Macrophages
More informationMycobacterial diseases developed during anti-tumour necrosis factor-a therapy
ORIGINAL ARTICLE PULMONARY INFECTIONS Mycobacterial diseases developed during anti-tumour necrosis factor-a therapy Jung-Wan Yoo 1, Kyung-Wook Jo 1, Bo-Hyung Kang 1, Mi Young Kim 2, Bin Yoo 3, Chang-Keun
More informationMycobacterial Infections: What the Primary Provider Should Know about Tuberculosis
Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Epidemiology Diagnosis of active TB Screening
More informationTesting for Tuberculosis Infection and Disease: The Expanding Role of Blood-based Assays
Complimentary CME Testing for Tuberculosis Infection and Disease: The Expanding Role of Blood-based Assays POWERED BY Program Description Screening and testing guidelines are an important component in
More informationIsoniazid treatment for latent tuberculosis infection is tolerable for rheumatoid arthritis patients receiving tumor necrosis factor inhibitor therapy
ORIGINAL ARTICLE 2017 Mar 13. [Epub ahead of print] Isoniazid treatment for latent tuberculosis infection is tolerable for rheumatoid arthritis patients receiving tumor necrosis factor inhibitor therapy
More informationCell-Mediated Immunity and T Lymphocytes
Cell-Mediated Immunity and T Lymphocytes T helper (Th) Cells Peripheral lymhoid tissue thymus Lymphoid stem cell CD8+ CD4+ CD4+ Treg CD8+ CTL + antigen Cytotoxic T lymphocyte CD4+ Th Helper T cell CD4+
More informationMonitoring Patients on Biologic Therapies Murlidhar Rajagopalan, MBBS, MD
Monitoring Patients on Biologic Therapies Murlidhar Rajagopalan, MBBS, MD Biologics available for psoriasis 1) tumor necrosis factor alpha (TNF-α) inhibitors, 2) interleukin (IL)-12/23 inhibitors, and
More informationLatent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016
Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016 Randy Culpepper, MD, MPH Deputy Heath Officer/Medical Director Frederick County Health Department March 16, 2016 2 No
More informationTesting for TB. Bart Van Berckelaer Territory Manager Benelux. Subtitle
Testing for TB Bart Van Berckelaer Territory Manager Benelux Subtitle Agenda TB infection pathway TB immunisation Testing options Pre lab considerations of the whole blood ELISA test The T-SPOT.TB test
More information2. Methods of Tuberculosis Screening
2. Methods of Tuberculosis Screening Diagnosis of active or latent TB involves a number of tests. There is no gold standard for determining whether a person is infected with M. tuberculosis but in practice
More informationAmjevita (adalimumab-atto) CG-DRUG-64, CG-DRUG-65
Market DC Amjevita (adalimumab-atto) CG-DRUG-64, CG-DRUG-65 Override(s) Prior Authorization Quantity Limit Medications Amjevita 20 mg/0.4 ml prefilled syringe Amjevita (adalimumab-atto) 40 mg/0.8 ml 2
More informationDIAGNOSIS AND MEDICAL MANAGEMENT OF TB DISEASE
DIAGNOSIS AND MEDICAL MANAGEMENT OF TB DISEASE Annie Kizilbash MD, MPH Assistant Professor University of Texas Health Science Center Staff Physician, Texas Center for Infectious Diseases TB Nurse Case
More informationDiagnosis and Medical Management of Latent TB Infection
Diagnosis and Medical Management of Latent TB Infection Marsha Majors, RN September 7, 2017 TB Contact Investigation 101 September 6 7, 2017 Little Rock, AR EXCELLENCE EXPERTISE INNOVATION Marsha Majors,
More informationPediatric TB Lisa Armitige, MD, PhD September 28, 2011
TB Nurse Case Management Davenport, Iowa September 27 28, 2011 Pediatric TB Lisa Armitige, MD, PhD September 28, 2011 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interest.
More informationScreening and Treatment Recommendations for Persons Exposed to MDR TB
Screening and Treatment Recommendations for Persons Exposed to MDR TB Although all persons at increased risk of tuberculosis (TB) infection should be screened for TB infection per USPTF/CDC guidelines
More informationThorax Online First, published on December 8, 2009 as /thx
Thorax Online First, published on December 8, 2009 as 10.1136/thx.2009.119677 Title Page Cost effectiveness of the NICE guidelines for screening for latent tuberculosis infection: the Quantiferon-TB gold
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Adaptive immune response biologic response modifiers and, 735 737 S-Adenosylmethionine (SAMe) for hepatitis, 825 826 Albinterferon for hepatitis,
More informationCimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Cimzia Page: 1 of 5 Last Review Date: March 17, 2017 Cimzia Description Cimzia (certolizumab pegol)
More informationManagement of Pediatric Tuberculosis in New Jersey
Management of Pediatric Tuberculosis in New Jersey Helen Aguila, MD NJMS Global TB Institute December 15, 2011 This presentation is in part adapted from Pediatric Tuberculosis by Ann Loeffler, MD : Francis
More informationTUBERCULOSIS. Pathogenesis and Transmission
TUBERCULOSIS Pathogenesis and Transmission TUBERCULOSIS Pathogenesis and Transmission Infection to Disease Diagnostic & Isolation Updates Treatment Updates Pathogenesis Droplet nuclei of 5µm or less are
More informationClinical features of active tuberculosis that developed during anti-tumor necrosis factor therapy in patients with inflammatory bowel disease
ORIGINAL ARTICLE pissn 1598-9100 eissn 2288-1956 http://dx.doi.org/10.5217/ir.2016.14.2.146 Intest Res 2016;14(2):146-151 Clinical features of active tuberculosis that developed during anti-tumor necrosis
More informationBarbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and Infectious Disease UT Health Northeast
Practical Aspects for Using the Interferon Gamma Release Assay (IGRA) Test Live Webinar July 14, 2017 Barbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and
More informationTB Intensive Tyler, Texas December 2-4, 2008
TB Intensive Tyler, Texas December 2-4, 2008 Interferon Gamma Releasing Assays: Diagnosing TB in the 21 st Century Peter Barnes, MD December 2, 2008 TOPICS Use of interferon-gamma release assays (IGRAs)
More informationCoordinating with Public Health on Tuberculosis Testing & Treatment
Coordinating with Public Health on Tuberculosis Testing & Treatment Bernadette Jakeman, PharmD, PhC, BCPS, AAHIVP Associate Professor University of New Mexico College of Pharmacy Objectives 1. Identify
More informationKJLM. Serial Interferon-gamma Release Assays for the Diagnosis of Latent Tuberculosis Infection in Patients Treated with Immunosuppressive Agents
Korean J Lab Med 2011;31:271-278 Original Article Diagnostic Immunology KJLM Serial Interferon-gamma Release Assays for the Diagnosis of Latent Tuberculosis Infection in Patients Treated with Immunosuppressive
More informationCHILDHOOD TUBERCULOSIS: NEW WRINKLES IN AN OLD DISEASE [FOR THE NON-TB EXPERT]
CHILDHOOD TUBERCULOSIS: NEW WRINKLES IN AN OLD DISEASE [FOR THE NON-TB EXPERT] QUESTION: : Which children in the United States should get a tuberculin skin test? Do questionnaires really work? Jeffrey
More informationLatent Tuberculosis Best Practices
Latent Tuberculosis Best Practices Last Updated September 7, 2016 LTBI Demographics in the US o 13million people in the US with LTBI (estimate) o In 2014, approximately 66% of TB cases in the United States
More informationATTACHMENT 2. New Jersey Department of Health Tuberculosis Program FREQUENTLY ASKED QUESTIONS
1. QUESTION Is it required to submit the Annual Report of TB Testing in Schools Form (TB-57) to the New Jersey Department of Health,? NO. The TB-57 form is completed by the school nurse and kept on-site
More informationValidity of interferon-c-release assays for the diagnosis of latent tuberculosis in haemodialysis patients
ORIGINAL ARTICLE BACTERIOLOGY Validity of interferon-c-release assays for the diagnosis of latent tuberculosis in haemodialysis patients W. K. Chung 1,2, Z. L. Zheng 1, J. Y. Sung 1, S. Kim 1,H.H.Lee 1,
More informationCOFM Immunization Policy 2016
COFM Immunization Policy 2016 Council of Ontario Faculties of Medicine June 2016 COUNCIL OF ONTARIO FACULTIES OF MEDICINE An affiliate of the Council of Ontario Universities COFM Immunization Policy 2016
More informationDiagnosis and Treatment of Tuberculosis, 2011
Diagnosis of TB Diagnosis and Treatment of Tuberculosis, 2011 Alfred Lardizabal, MD NJMS Global Tuberculosis Institute Diagnosis of TB, 2011 Diagnosis follows Suspicion When should we Think TB? Who is
More informationAdvanced Management of Patients with Tuberculosis Little Rock, Arkansas August 13 14, 2014
Advanced Management of Patients with Tuberculosis Little Rock, Arkansas August 13 14, 2014 Tuberculosis Pathogenesis and Treatment of Latent TB Infection Lisa Armitige, MD, PhD August 13, 2014 Lisa Armitige,
More informationA Case of Tuberculous Arthritis Following the Use of Etanercept
CASE REPORT DOI: 10.3904/kjim.2009.24.4.397 A Case of Tuberculous Arthritis Following the Use of Etanercept Seung Won Choi 1, Jong Joon Ahn 1, Young Tae Hwang 1, Sang Hoon Koh 2, and Sung Do Cho 2 Departments
More informationDelayed response to anti-tuberculosis treatment in a patient on infliximab
Respiratory Medicine (2005) 99, 648 652 CASE REPORT Delayed response to anti-tuberculosis treatment in a patient on infliximab Elina Vlachaki a, Kostas Psathakis a,, Kostas Tsintiris a, Alexios Iliopoulos
More information